BCMA CAR-T细胞治疗复发/难治性浆母细胞淋巴瘤:个案研究与临床启示

BCMA CAR-T cell therapy for relapsed/refractory plasmablastic lymphoma:case report and clinical implication

浆母细胞淋巴瘤(plasmablastic lymphoma,PBL)是一种罕见的侵袭性大B细胞淋巴瘤亚型,预后较差且目前缺乏标准治疗方案。常用的治疗策略包括化疗、蛋白酶体抑制剂、免疫调节剂、CD30和CD38单克隆抗体以及自体造血干细胞移植等均未获得理想的治疗结果。嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞疗法已为弥漫性大B细胞淋巴瘤和多发性骨髓瘤的管理带来了变革,这也为PBL患者带来了希望。然而,目前尚缺乏CAR-T细胞在PBL治疗中应用的经验及数据支持。本文报告1例老年PBL患者在接受B细胞成熟抗原CAR-T细胞治疗后获得完全缓解的经验。

Plasmablastic lymphoma(PBL)is a rare and aggressive subtype of large B-cell lymphoma,with a poor prognosis without standardized treatment protocols.Traditional therapeutic strategies,such as chemotherapy,proteasome inhibitors,immunomodulatory agents,CD30 and CD38 monoclonal antibodies,and autologous hematopoietic stem cell transplantation,have yielded suboptimal outcomes.Chimeric antigen receptor T(CAR-T)cell therapy has revolutionized the management of diffuse large B-cell lymphoma and multiple myeloma,offering hope for patients with PBL.However,clinical experience and data evidence supporting the application of CAR-T cell in PBL treatment remain scant.This paper reports a case of an elderly patient with PBL who achieved a complete response following B-cell maturation antigen CAR-T cell therapy.